Renal & Urinary

Contrast-induced nephropathy: prevention and risk assessment

Clinical Overview and When to Suspect Contrast-Induced Nephropathy

— Contrast-induced nephropathy (CIN) is the subset where contrast is the presumed causal agent, after exclusion of alternative causes (hypotension, nephrotoxins, atheroemboli, sepsis).

— Diabetic with CKD who just had a coronary angiogram and now has rising creatinine at 48 h

— Elderly patient with CHF who received CT pulmonary angiogram for suspected PE

— Post-procedure outpatient calling clinic with decreased urine output after cardiac cath

— General population: <1–2%

— eGFR 30–59 + diabetes: ~10%

— eGFR <30: 20–30%

— Emergent PCI in shock: up to 50%

Board pearl: The 2020 ACR–NKF consensus statement reframed most "CIN" as CA-AKI because true contrast causation is rarer than historically thought — and IV contrast in eGFR ≥30 carries minimal risk. Withholding indicated contrast imaging causes more harm than CA-AKI in most scenarios.

Definition (KDIGO/ACR consensus): Contrast-associated acute kidney injury (CA-AKI) is a rise in serum creatinine ≥0.3 mg/dL within 48 h, ≥1.5× baseline within 7 days, or urine output <0.5 mL/kg/h for ≥6 h, occurring after intravascular iodinated contrast exposure.

Pathophysiology: Direct tubular toxicity from iodinated contrast + medullary vasoconstriction (endothelin/adenosine-mediated) + osmotic stress → ischemic ATN in the outer medulla.

Typical course: Creatinine rises within 24–48 h, peaks at day 3–5, returns to baseline by day 7–14. Oliguria is uncommon; most cases are nonoliguric and self-limited.

When to suspect on Step 3:

Incidence stratification:

Step 3 management: When CIN is suspected, the workhorse evaluation is checking creatinine 48–72 h post-contrast in at-risk outpatients and reviewing the timeline against alternative insults (NSAIDs, ACEi started same week, hypovolemia, sepsis). Causality requires exclusion, not just temporal association.

Presentation Patterns and Key History

— Decreased urine output, lower-extremity edema, weight gain

— Fatigue, nausea, anorexia if BUN climbs significantly

— Dyspnea/orthopnea if volume overload supervenes (especially post-cath patients with CHF)

— Exact timing and type of contrast: iodinated (CT, angiography, PCI) vs gadolinium (MRI — different risk, NSF not CIN). Intra-arterial first-pass (coronary, aortic root) > intra-arterial second-pass > IV exposure.

— Volume of contrast: Risk rises sharply when contrast volume (mL) exceeds 3× eGFR or the Mehran threshold.

— Baseline renal function: Most recent creatinine/eGFR; trajectory over prior 6–12 months

— Comorbidities: Diabetes (especially with proteinuria), CHF (EF <40%), age >75, anemia (Hct <39% men/<36% women), hypotension/IABP use

— Concurrent nephrotoxins: NSAIDs, ACEi/ARB, aminoglycosides, amphotericin, high-dose loop diuretics, recent contrast within 72 h

— Volume status before contrast: NPO duration, vomiting, diuretic dosing

Step 3 management: In the ambulatory follow-up visit after recent contrast, always reconcile the medication list — ensure ACEi/ARB and metformin decisions were appropriately documented and that a 48–72 h creatinine was obtained in at-risk patients before resuming nephrotoxic agents.

Classic presentation: Asymptomatic creatinine bump detected on routine post-procedure labs 24–72 h after iodinated contrast. Most patients feel well; severe AKI with uremic symptoms is rare.

Symptomatic presentations (uncommon but testable):

Critical history elements to elicit:

Key distinction: CIN vs cholesterol atheroembolic disease after arterial catheterization — both follow angiography, but atheroemboli typically present 3–8 weeks later with livedo reticularis, blue toes, eosinophilia, hypocomplementemia, and progressive (not self-limited) renal decline.

Red flag history: Patient on metformin who received contrast and now has lactic acidosis symptoms (abdominal pain, hyperventilation, AMS) — metformin should have been held in high-risk patients.

Physical Exam Findings and Hemodynamic Assessment

— Hypovolemia clues: Dry mucous membranes, flat JVP, orthostasis, tachycardia, decreased skin turgor, low urine output, BUN:Cr >20:1. These patients are at highest risk and need pre-procedure isotonic fluids.

— Euvolemia/hypervolemia: Elevated JVP (>8 cm), S3, bibasilar crackles, peripheral edema, hepatojugular reflux. Aggressive pre-hydration here can precipitate pulmonary edema — use cautious individualized fluids or consider LVEDP-guided hydration.

— New S3 or worsening crackles post-procedure suggest volume overload from prophylactic fluids — consider diuresis

— Hypotension intra/post-procedure markedly increases CIN risk (Mehran score weights hypotension and IABP use heavily)

— Livedo reticularis, blue toe syndrome, Hollenhorst plaques on fundoscopy → atheroembolic disease, not CIN

— Petechiae/purpura → consider TTP, vasculitis as alternative AKI cause

CCS pearl: On a CCS case of post-PCI rising creatinine, order vital signs, daily weights, strict I/Os, and a bladder scan before assuming CIN. Catch obstruction and volume overload early — they are reversible and frequently tested as the "real" diagnosis when the stem looks like CIN.

Board pearl: A patient who develops AKI 4 weeks after a complex aortic procedure with livedo reticularis, eosinophilia, and low complement has cholesterol embolization syndrome — not CIN. This is a high-yield distractor.

General appearance: Most CIN patients look well. Findings are driven by volume status, underlying CHF, and severity of AKI.

Volume status assessment (central to both prevention and post-event management):

Cardiovascular:

Skin (look for mimics):

Neurologic: Asterixis, encephalopathy only with severe uremia (rare in CIN).

Bladder/abdominal exam: Palpable bladder or suprapubic tenderness — exclude post-procedural urinary retention (a common AKI mimic, especially after sedation or anticholinergic exposure during cath).

Diagnostic Workup — Initial Labs, Imaging, and Biomarkers

— Serum creatinine and eGFR at baseline, then 48–72 h after contrast in at-risk patients (eGFR <30, or 30–44 with diabetes, or AKI within 6 weeks)

— BMP: track K⁺ (rises in AKI), bicarbonate (acidosis), BUN:Cr ratio

— CBC: anemia is a modifiable Mehran risk factor; eosinophilia suggests atheroemboli or AIN

— Urinalysis with microscopy: Muddy brown granular casts → ATN (consistent with CIN). WBC casts/eosinophils → AIN. Dysmorphic RBCs/RBC casts → glomerular disease.

— Urine sodium and FeNa: CIN is an ischemic ATN variant, but FeNa is often paradoxically <1% early due to intense renal vasoconstriction — a classic exam point that distinguishes CIN from typical ATN.

— Fractional excretion of urea (FeUrea) <35% also supports CIN even on diuretics.

— Renal ultrasound to exclude obstruction whenever AKI workup is performed — particularly in post-procedure patients who may have retention or, rarely, retroperitoneal hematoma compressing ureters after femoral access

— Bladder scan to rule out retention before invasive workup

— NGAL, KIM-1, cystatin C, and urinary [TIMP-2]×[IGFBP-7] (NephroCheck) detect tubular injury earlier than creatinine but are not standard of care for CIN diagnosis

Key distinction: FeNa <1% in CIN vs FeNa >2% in classic ATN. CIN behaves "prerenal-like" in urine chemistries despite tubular injury because of profound medullary vasoconstriction. Step 3 stems love this nuance.

Step 3 management: In any at-risk patient, document a 48–72 h creatinine before refilling ACEi/ARB, NSAIDs, or metformin. Skipping this step is both a board pitfall and a real-world patient safety gap.

Core labs (at-risk patient pre- and post-contrast):

Imaging:

Biomarkers (emerging, not routinely required for Step 3):

ECG: Obtain if hyperkalemia is suspected (peaked T waves, widened QRS).

Diagnostic Workup — Advanced or Confirmatory Studies

— Creatinine still rising at day 5–7 (CIN should peak by day 3–5 and improve)

— Oliguria/anuria (atypical for CIN)

— Active urinary sediment (casts, hematuria, proteinuria)

— Systemic features (rash, eosinophilia, fever, arthralgias)

— Renal ultrasound with Doppler: rule out obstruction, renal artery dissection (post-cath), or renal vein thrombosis

— Urine protein:creatinine ratio: nephrotic-range proteinuria suggests glomerular disease, not CIN

— Serologies if vasculitis/glomerular disease suspected: ANA, ANCA, anti-GBM, complements (C3/C4), hepatitis B/C, cryoglobulins, SPEP/UPEP, free light chains

— Complement levels and eosinophil count: low C3 + eosinophilia + livedo + delayed onset post-cath → atheroembolic disease

— Renal biopsy: Reserved for refractory or atypical AKI — shows ATN with vacuolated tubular epithelium in CIN; cholesterol clefts in atheroemboli; interstitial eosinophils in AIN

— Day 2, day 3, day 5, and day 7 in hospitalized at-risk patients

— Outpatient: 48–72 h post-contrast labs are the standard

Board pearl: A 70-year-old with normocytic anemia, back pain, hypercalcemia, and AKI after CT with contrast → multiple myeloma, not isolated CIN. Contrast is no longer an absolute contraindication in myeloma, but volume depletion and light chain cast nephropathy must be addressed.

Key distinction: CIN improves by day 7–14; atheroembolic AKI progresses over weeks and often requires dialysis.

CIN is a clinical diagnosis of exclusion — there is no confirmatory test. The workup focuses on ruling out competing etiologies of post-contrast AKI.

When to broaden the workup:

Targeted advanced studies:

Repeat creatinine timing:

Multiple myeloma consideration: In elderly patients with unexplained AKI post-contrast plus anemia, hypercalcemia, or bone pain, send SPEP/UPEP and free light chains — myeloma cast nephropathy can be triggered or unmasked by contrast and volume depletion.

Risk Stratification and First-Line Management Logic

— Mehran risk score (post-PCI): hypotension (5), IABP (5), CHF (5), age >75 (4), anemia (3), diabetes (3), contrast volume (1 per 100 mL), eGFR (2–6 points). Score ≥16 → ~57% CIN risk, ~12% dialysis risk.

— Mehran-2 updated for modern PCI populations

— Non-modifiable: age >75, diabetes with CKD, baseline eGFR <60 (especially <30), CHF/EF<40, prior CIN, multiple myeloma with light chain disease, kidney transplant

— Modifiable: volume depletion, concurrent nephrotoxins, anemia, hypotension, contrast volume, repeat contrast within 72 h

— eGFR ≥45 (non-diabetic) or ≥60: Contrast is safe; routine hydration only if clinically dehydrated

— eGFR 30–44: Use prophylactic IV isotonic fluids; minimize contrast volume; hold nephrotoxins

— eGFR <30 or AKI: Weigh risk/benefit carefully; if essential, use iso-osmolar or low-osmolar contrast, minimum volume, IV isotonic fluids, and have nephrology aware

— On dialysis with no residual function: Contrast is generally safe (no remaining kidneys to protect); no urgent post-contrast HD required

— NSAIDs, aminoglycosides — hold

— ACEi/ARB — controversial; many centers continue, but hold in volume-depleted or eGFR <30

— Metformin — hold at time of contrast in eGFR <30 or AKI; resume 48 h later after creatinine check

— SGLT2 inhibitors — hold for 3 days periprocedurally (euglycemic DKA risk with NPO + AKI)

— Diuretics — hold morning of procedure if volume-depleted

Step 3 management: The single highest-yield prevention intervention is IV isotonic crystalloid hydration in at-risk patients with eGFR <30 or 30–44 + diabetes/CHF. Everything else (NAC, bicarbonate, statins) is secondary or unproven.

Validated risk tools:

Major modifiable and non-modifiable risk factors:

Pre-procedure decision algorithm:

Hold list pre-contrast:

Pharmacotherapy and Prophylactic Regimens — First-Line

— Normal saline 0.9% or isotonic sodium bicarbonate (154 mEq/L) — both acceptable; the PRESERVE trial (2018) showed no difference between them

— Standard regimen: 1–1.5 mL/kg/h IV starting 6–12 h before and continuing 6–12 h after contrast (total ~1 L pre, ~1 L post in most adults)

— Outpatient abbreviated regimen: 3 mL/kg over 1 h before, then 1–1.5 mL/kg/h for 4–6 h after

— Adjust in CHF: reduce rate to 0.5 mL/kg/h or use LVEDP-guided hydration (POSEIDON trial protocol)

— PRESERVE trial showed no benefit over placebo for preventing CIN, MAKE, or death

— No longer recommended by ACR/NKF or KDIGO, despite older USMLE-style teaching

— Board pearl: If NAC appears as an answer choice for CIN prophylaxis, it is now generally a distractor unless paired with IV fluids in a legacy question

— Iso-osmolar (iodixanol) or low-osmolar nonionic (iohexol, iopamidol) preferred over high-osmolar

— Minimize volume: Target contrast volume (mL) / eGFR ratio < 3

— Mannitol — harmful

— Loop diuretics for "renal protection" — harmful unless treating volume overload

— Fenoldopam, theophylline, dopamine — not recommended

— Prophylactic hemofiltration/hemodialysis — not recommended

Key distinction: Volume expansion with isotonic fluids is the only proven prevention. NAC is out; mannitol and furosemide are harmful for prevention.

IV isotonic crystalloid (cornerstone):

Oral hydration: Inferior to IV in high-risk patients; acceptable only in low-risk outpatients

N-acetylcysteine (NAC):

Sodium bicarbonate: Equivalent to saline (PRESERVE); use either

Statins: Some evidence for high-dose statin (rosuvastatin 40 mg or atorvastatin 80 mg) pre-PCI in statin-naïve patients — reasonable but not universal

Contrast agent choice:

Hold concurrent nephrotoxins (see prior chunk).

Things that do NOT work (or harm):

Procedural Considerations and Alternative Imaging Strategies

— Target contrast volume (mL) < 3 × eGFR; ideally < eGFR for high-risk

— Use biplane angiography, automated injectors, and IVUS/OCT to reduce dye burden during PCI

— Stage interventions: diagnostic cath now, PCI in 1–2 weeks to allow renal recovery

— Non-contrast CT for nephrolithiasis, acute stroke (initial), most trauma surveys

— Ultrasound for cholecystitis, DVT, AAA surveillance, renal anatomy

— MRI without gadolinium for many CNS/MSK indications

— V/Q scan instead of CTPA for PE in CKD (preferred if CXR clear and no chronic lung disease)

— MR angiography without contrast (time-of-flight) for vascular imaging in select cases

— Gadolinium does not cause CIN, but nephrogenic systemic fibrosis (NSF) is a concern in eGFR <30 or AKI

— Group II macrocyclic agents (gadobutrol, gadoteridol, gadoterate) carry negligible NSF risk even in advanced CKD per ACR 2020

— Avoid repeat iodinated contrast within 48–72 h unless clinically essential

— Avoid intraprocedural hypotension (MAP <65); each episode amplifies CIN risk

— IABP use is itself a major risk factor (Mehran)

— Continue IV isotonic fluids 6 h post

— Check creatinine at 48–72 h

— Resume metformin only after creatinine confirmed stable

— Monitor urine output, daily weights, K⁺ and bicarbonate if AKI develops

CCS pearl: When ordering a CT with contrast for an at-risk patient, the high-yield CCS bundle is: basic metabolic panel, IV NS 1 mL/kg/h × 12 h before and after, hold metformin and NSAIDs, choose low-osmolar contrast, recheck creatinine at 48–72 h. Forgetting the post-procedure creatinine check is a common scoring miss.

Minimize contrast volume:

Avoid contrast when alternative imaging suffices:

Gadolinium considerations (separate risk):

Repeat contrast spacing:

Procedural hemodynamics:

Post-procedure orders (CCS-style):

Special Populations — Elderly and Renal/Hepatic Impairment

— Age is an independent Mehran risk factor (4 points)

— Reduced renal reserve, polypharmacy, higher rates of CHF and DM — all compound risk

— Use estimated eGFR rather than creatinine alone; sarcopenia falsely lowers creatinine and overestimates GFR. Consider cystatin C-based eGFR in frail elders

— Adjust hydration rate downward (0.5–1 mL/kg/h) if CHF or LVH; monitor for pulmonary edema

— eGFR ≥45: minimal risk; standard precautions

— eGFR 30–44: moderate risk; IV hydration, minimize volume, hold nephrotoxins

— eGFR 15–29: high risk; nephrology consultation, weigh alternative imaging, use iso-osmolar contrast, smallest possible volume

— eGFR <15 not on dialysis: highest risk for tipping into dialysis; some centers arrange standby HD, though prophylactic HD is not recommended

— Dialysis-dependent ESRD with anuria: contrast is generally safe; no urgent post-contrast HD needed (kidney already nonfunctional)

— Dialysis-dependent with residual urine output: treat as CKD; protect residual function with hydration and minimal contrast

— Solitary functioning kidney with potential calcineurin inhibitor nephrotoxicity → treat as CKD; check tacrolimus level; hold ACEi/ARB; aggressive hydration

— Hepatorenal physiology with effective arterial underfilling mimics volume depletion → high CIN risk

— Use IV albumin or careful saline; avoid large-volume paracentesis pre-contrast without replacement

— Hold diuretics and nonselective beta-blockers' contributing factors as feasible

Step 3 management: In the cirrhotic patient needing contrast (e.g., CT for HCC screening), check baseline renal function, avoid concurrent diuretic intensification, hydrate cautiously, and recheck creatinine at 48–72 h. Hepatorenal syndrome can masquerade as CIN.

Board pearl: Frail elderly creatinine of "1.0" may correspond to eGFR <45 — always calculate, never eyeball.

Elderly (>75):

CKD stages:

Kidney transplant recipients:

Hepatic impairment / cirrhosis:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Iodinated contrast crosses the placenta but is not teratogenic; fetal thyroid concerns are theoretical, and ACR recommends iodinated contrast only when essential

— Gadolinium is generally avoided in pregnancy (associated with stillbirth, rheumatologic/inflammatory conditions in offspring — ACR Category C)

— Maternal CIN risk in pregnancy is low (young, healthy kidneys) but volume status fluctuates rapidly — ensure euvolemia

— Lactation: Both iodinated and gadolinium contrast are safe; <1% excreted in breast milk; no need to pump-and-dump per ACR

— CIN is rare in children with normal baseline renal function

— High-risk pediatric groups: congenital heart disease post-cath, oncology patients on cisplatin/methotrexate, neonates

— Weight-based hydration: 1–1.5 mL/kg/h isotonic fluid; cap at adult rates

— Calculate eGFR using bedside Schwartz equation (0.413 × height/Cr)

— Highest-yield population on Step 3

— DM + CKD synergistically multiply CIN risk

— Metformin: Hold at time of contrast if eGFR <30 or AKI; do not routinely hold for eGFR ≥30 with stable function per current ACR/FDA guidance. Resume after 48-h creatinine check confirms stability.

— SGLT2 inhibitors: Hold 3 days periprocedurally

— Historically considered a contraindication; current guidance permits contrast if well-hydrated and not in active light-chain cast nephropathy

— Major risk factor; use LVEDP-guided hydration (POSEIDON: hold hydration if LVEDP >18) to balance prevention vs pulmonary edema

Key distinction: Gadolinium = NSF risk in CKD/AKI (and avoid in pregnancy); iodinated = CIN risk but generally safe in lactation and in pregnancy when medically necessary.

Pregnancy:

Pediatrics:

Diabetes mellitus:

Multiple myeloma:

Heart failure / EF <40%:

Renal transplant donors and recipients: treat as solitary kidney; aggressive prevention.

Complications and Adverse Outcomes

— Mild, self-limited AKI (most common): Creatinine bump 0.3–1.0 mg/dL, returns to baseline within 7–14 days, no clinical consequence

— Moderate AKI: Symptomatic volume overload, electrolyte derangement, requires hospitalization or prolongs stay

— Severe AKI requiring RRT: 0.5–12% depending on baseline risk; Mehran score ≥16 ~12% dialysis

— Permanent renal impairment / progression to ESRD: Uncommon but described, particularly in high-risk diabetic CKD

— Hyperkalemia with arrhythmia risk — monitor ECG, treat with calcium/insulin/glucose/kayexalate-alternatives as needed

— Metabolic acidosis — worsened by metformin retention (lactic acidosis) if not held

— Volume overload / pulmonary edema from overzealous prophylactic hydration in CHF patients

— Uremic complications: pericarditis, encephalopathy, bleeding (rare)

— CIN is associated with increased 30-day and 1-year mortality post-PCI, increased MACE, longer hospital LOS

— Whether CIN is causal or a marker of frail patients remains debated

— Cutaneous rash 1–7 days post-contrast — distinct from renal injury

— Progressive renal failure, livedo, blue toes, eosinophilia, hypocomplementemia, GI ischemia — much worse prognosis than CIN

— Pulmonary edema from over-hydration

— Hypoglycemia from metformin discontinuation without bridging

— DKA from inappropriate SGLT2 hold/restart timing

— Delayed/missed diagnoses from withholding indicated contrast

Board pearl: Withholding necessary CT angiography for suspected PE or aortic dissection out of CIN fear has a higher mortality than CIN itself in most patients with eGFR ≥30. Choose the test that answers the clinical question.

Spectrum of severity:

Specific complications:

Downstream cardiovascular consequences:

Delayed contrast reactions (separate, not CIN):

Cholesterol embolization (post-arterial cath mimic):

Iatrogenic harms from prevention itself:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Creatinine rise >50% from baseline or doubling

— Oliguria (<0.5 mL/kg/h for >6 h) post-contrast

— Hyperkalemia (K⁺ >6.0) or metabolic acidosis (HCO₃ <15) not rapidly corrected

— Volume overload refractory to diuretics

— Suspected alternative diagnosis (atheroemboli, AIN, glomerulonephritis)

— eGFR <15 pre-procedure, to coordinate periprocedural plan

— Hemodynamic instability post-procedure

— Severe hyperkalemia with ECG changes

— Acute pulmonary edema requiring BiPAP or intubation

— Need for emergent RRT

— Concurrent cardiogenic shock post-PCI

— Acidosis refractory (pH <7.1)

— Electrolytes (refractory hyperkalemia)

— Ingestions (not typically CIN-related)

— Overload (refractory pulmonary edema)

— Uremia (pericarditis, encephalopathy, bleeding)

— Admit: symptomatic AKI, K⁺ >6, volume overload, oliguria, comorbid decompensation

— Outpatient monitoring acceptable: asymptomatic creatinine rise <50% in a stable patient with reliable follow-up — repeat labs in 48–72 h, hold nephrotoxins, ensure adequate PO intake

— Post-PCI patients with rising creatinine warrant joint cards-nephro management

— Consider staging future interventions to limit cumulative contrast

CCS pearl: On a CCS case, the trigger to "Consult nephrology" is generally creatinine doubling, K⁺ >6.0, or oliguria — order this early, not after dialysis is already needed. Also order strict I/Os, daily weights, telemetry for K⁺ >5.5, and a renal diet (low K⁺, low phosphorus, fluid restriction if overloaded).

Step 3 management: Transition-of-care risk: every patient discharged after contrast exposure with elevated creatinine needs a documented PCP follow-up in 5–7 days with repeat BMP.

Nephrology consultation indications:

ICU triage:

Indications for renal replacement therapy (AEIOU):

Inpatient vs outpatient management:

Cardiology / interventional consultation:

Key Differentials — Other Renal/Tubular Causes of AKI

— Sepsis, hypotension, prolonged surgery, aminoglycosides, amphotericin, cisplatin

— Muddy brown casts, FeNa >2%, slower recovery than CIN

— Key distinction: CIN has FeNa <1% early (vasoconstriction); classic ATN has FeNa >2%

— Drug-induced (PPIs, NSAIDs, beta-lactams, sulfa, allopurinol)

— Triad (rare): fever, rash, eosinophilia; WBC casts, urinary eosinophils, pyuria

— Timing: 7–10 days after drug exposure (longer than CIN)

— Post–arterial catheterization, delayed 3–8 weeks

— Livedo reticularis, blue toes, Hollenhorst plaques, eosinophilia, hypocomplementemia, progressive renal decline

— Treatment: supportive; statins; avoid anticoagulation if possible (may worsen)

— BUN:Cr >20, FeNa <1%, bland urine

— Responds to volume challenge; CIN does not respond as briskly

— Always exclude with bladder scan and/or renal US

— Especially relevant in post-procedural patients with sedation, anticholinergics, or pelvic surgery

— Look for elevated CK, positive UA blood without RBCs (myoglobin), tea-colored urine

— Worsening renal function in setting of decompensated CHF; often coexists with CIN post-PCI

Key distinction: Timing is the differential's best friend — CIN at 24–72 h, AIN at 7–10 days, atheroemboli at weeks. Anchoring on timing alone solves many exam stems.

Board pearl: Eosinophiluria is nonspecific — present in AIN, atheroembolic disease, and even UTIs. Don't anchor on it as pathognomonic for AIN.

Acute tubular necrosis (non-contrast ischemic or nephrotoxic ATN):

Acute interstitial nephritis (AIN):

Cholesterol atheroembolic disease:

Prerenal AKI from volume depletion or hepatorenal:

Postrenal / obstructive AKI:

Pigment nephropathy (rhabdomyolysis, hemolysis):

Cardiorenal syndrome:

Key Differentials — Other-Category Causes

— Post-procedural fever/leukocytosis with AKI — consider line infection, UTI from catheterization, contrast media reaction

— Treat sepsis first; renal recovery follows source control

— Post-PCI AKI in a patient with low cardiac output is often cardiorenal, not CIN — assess EF, lactate, mixed venous saturation

— Post–femoral access patient with flank pain, hypotension, and AKI — get non-contrast CT abdomen; treat with reversal, transfusion, possible IR

— Tense abdomen, decreased UOP, elevated bladder pressure (>20 mmHg) → surgical decompression

— Cirrhotic with contrast exposure and AKI — distinguish HRS-AKI from CIN by lack of response to albumin challenge, very low urine sodium (<10), bland sediment, and clinical context. Treat HRS with albumin + terlipressin (or midodrine/octreotide where terlipressin unavailable).

— Vancomycin trough toxicity, tenofovir, acyclovir crystal nephropathy, methotrexate

— Review every drug given periprocedurally

— Active sediment, nephrotic-range proteinuria, low complements, positive serologies — refer for biopsy

— Schistocytes, thrombocytopenia, LDH elevated — consider TTP, HUS, drug-induced TMA (clopidogrel rare)

— In oncology patients receiving contrast for staging; check uric acid, K⁺, phosphate, calcium

— Distinct from CIN; presents as anaphylactoid (urticaria, bronchospasm, hypotension) within minutes — treat with epinephrine, antihistamines, steroids; not a renal phenomenon

Step 3 management: When AKI follows contrast, the differential is broader than CIN — always rule out competing diagnoses, especially obstruction, hypotension-related ATN, and atheroemboli. CIN is a diagnosis of exclusion.

Sepsis-associated AKI:

Cardiogenic shock / cardiorenal:

Bleeding / retroperitoneal hematoma:

Abdominal compartment syndrome:

Hepatorenal syndrome (HRS):

Drug-induced AKI (non-AIN):

Glomerular disease unmasked:

Thrombotic microangiopathy:

Tumor lysis syndrome:

Contrast media hypersensitivity reaction:

Secondary Prevention, Discharge Plan, and Long-Term Management

— Resume ACEi/ARB once creatinine is stable and within 25% of baseline; usually 48–72 h

— Resume metformin only after creatinine returns to baseline (typically 48 h post-contrast with documented stable eGFR ≥30)

— Resume SGLT2 inhibitors when patient is eating normally, hemodynamically stable, and AKI resolved

— Statin optimization: high-intensity statin for ASCVD secondary prevention post-PCI

— Avoid NSAIDs indefinitely in CKD stage 3b or worse; counsel on OTC products (ibuprofen, naproxen)

— Diuretic adjustment: reduce dose temporarily if volume-depleted; reassess at follow-up

— Educate about future contrast exposures — patient should disclose history of CIN/CKD at all imaging encounters

— Provide a written list of nephrotoxic medications to avoid

— Hydration before any future contrast study

— Recognize symptoms of recurrence: decreased UOP, edema, fatigue

— Patients with sustained creatinine elevation should be coded as AKI with risk of progression to CKD

— Repeat BMP at 1 week, 1 month, 3 months

— Add urine albumin:creatinine ratio at 3 months to screen for proteinuria

— Establish or maintain nephrology follow-up if eGFR remains <60 or proteinuria develops

— CIN is associated with worse long-term CV outcomes — intensify secondary prevention (BP <130/80, LDL <70 if ASCVD, A1c individualized 7–8%, smoking cessation)

— Flag chart with CIN history

— Prefer non-contrast modalities when adequate

— If contrast needed: pre-procedure hydration protocol, minimum volume, low/iso-osmolar agent

Board pearl: Even a single episode of CIN-associated AKI accelerates progression to CKD. The discharge plan must include a nephrology referral if eGFR <60 persists at 3 months, plus aggressive cardiovascular risk reduction.

Discharge medication reconciliation:

Patient counseling:

Long-term renal monitoring:

Cardiovascular risk:

Future imaging strategy:

Follow-Up, Monitoring Parameters, and Counseling

— 48–72 h: Initial post-contrast BMP — usually drawn at the imaging facility or PCP office

— 1 week: Phone or in-person follow-up if creatinine elevated; repeat BMP

— 2–4 weeks: Ensure creatinine has returned to baseline; resume held medications if not already

— 3 months: Reassess eGFR and urine ACR to determine if CKD has developed/progressed

— 6–12 months: Nephrology follow-up if persistent CKD

— Serum creatinine and eGFR trajectory

— Serum K⁺, bicarbonate, phosphate

— Urine output (in-hospital) and daily weights

— Urine ACR for proteinuria

— BP at every visit (target <130/80 in CKD)

— Hemoglobin (CKD-related anemia)

— Vitamin D, PTH, calcium, phosphate if eGFR <45 (CKD-MBD)

— Hydration: maintain adequate PO intake, especially in hot weather, GI illness, or with diuretics

— Medication safety: avoid NSAIDs, double-check OTC products and herbals (aristolochic acid), report all prescriptions to all providers

— Imaging disclosure: notify all clinicians of CKD/prior CIN

— Lifestyle: DASH-style diet, smoking cessation, weight management, exercise as tolerated

— Vaccinations: influenza annually, pneumococcal, hepatitis B (especially if approaching dialysis)

— Tight glycemic control individualized to age/comorbidity

— SGLT2 inhibitor for renal/cardiac protection if eGFR ≥20 and stable

— Annual urine ACR and dilated eye exam

— Cardiac rehab post-PCI improves outcomes even with CIN history

— Address frailty and sarcopenia in elderly

Step 3 management: The highest-yield follow-up checkpoint is the 48–72 h creatinine — missing it is both a board pitfall and a Joint Commission–flagged safety gap. Build it into discharge instructions explicitly.

Follow-up cadence (Step 3 outpatient logic):

Monitoring parameters:

Counseling priorities:

Diabetes-specific counseling:

Rehabilitation considerations:

Ethical, Legal, and Patient Safety Considerations

— Document discussion of CIN risk, allergic reaction risk, NSF risk (for gadolinium in CKD), and the alternatives (non-contrast imaging, no imaging)

— In emergent settings (stroke, dissection, massive PE), implied consent applies when life-threatening; document the urgency

— Edge case: Patient with severe CKD refuses contrast for suspected PE — document capacity assessment, explain mortality of missed PE vs CIN risk, offer V/Q scan as alternative; respect autonomy if capacity intact

— Medication reconciliation errors are the #1 source of preventable CIN-related harm — metformin not held, ACEi continued in volume depletion, NSAIDs not stopped

— Implement EHR alerts for eGFR <45 at contrast order entry

— Standardized hydration protocols reduce variability

— Closed-loop creatinine follow-up: EHR-enforced 48–72 h post-contrast BMP order is a Joint Commission/PSI-relevant safeguard

— Discharge summary must specify: date and type of contrast, baseline and discharge creatinine, medications held with restart instructions, follow-up creatinine timing, and PCP appointment

— Hand-off failures at hospital discharge cause readmission for AKI, hyperkalemia, or lactic acidosis from un-restarted metformin

— Severe contrast reactions and dialysis-requiring CIN are reportable to facility patient-safety systems; some states require reporting of dialysis-precipitating events

— Limited English proficiency and low health literacy patients are at higher risk of medication non-reconciliation post-procedure — use teach-back, interpreters, and written instructions in the patient's language

— Unnecessary repeat imaging or contrast avoidance both have measurable cost — value-based care frameworks favor risk-stratified, protocolized prevention

Board pearl: A patient who develops CIN after contrast was ordered without checking a recent creatinine in a known diabetic represents a system failure — the corrective action is a checklist/EHR hard-stop, not provider counseling alone (systems-based practice).

Informed consent for contrast studies:

Patient safety / system-level issues:

Transitions of care:

Mandatory reporting and adverse events:

Health equity:

Cost and value:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When in doubt on a Step 3 stem, the answer is almost always IV isotonic fluids for prevention and supportive care + holding nephrotoxins for treatment.

Timing: CIN creatinine rises 24–48 h, peaks day 3–5, resolves day 7–14

FeNa: Paradoxically <1% in CIN despite tubular injury — vasoconstriction physiology

Best prevention: IV isotonic crystalloid (NS or isotonic bicarb — equivalent per PRESERVE)

NAC: No longer recommended (PRESERVE trial negative)

Mannitol and furosemide: Harmful for prevention — never the right answer

Highest-risk population: Diabetic with CKD undergoing PCI with hypotension

Mehran score: Cumulative; ≥16 predicts severe CIN and dialysis

Contrast choice: Iso-osmolar (iodixanol) or low-osmolar nonionic preferred

Contrast volume rule: Keep mL of contrast < 3 × eGFR

Metformin: Hold at time of contrast if eGFR <30 or AKI; resume after 48 h with normal creatinine — fear is lactic acidosis from drug accumulation

SGLT2 inhibitors: Hold 3 days periprocedurally

ACEi/ARB: Hold if volume-depleted or eGFR <30; otherwise typically continue

Gadolinium ≠ CIN — risk is NSF in eGFR <30; Group II macrocyclics are low risk

Pregnancy: Iodinated contrast okay if essential; avoid gadolinium

Lactation: Both contrasts safe; no pump-and-dump needed

Dialysis patients with anuria: Contrast generally safe; no emergent HD needed

Multiple myeloma: Hydrate well; not absolute contraindication

Atheroembolic disease: 3–8 weeks post-cath, livedo, blue toes, eosinophilia, low complement

AIN: 7–10 days post-drug, WBC casts, urinary eosinophils

PRESERVE trial (2018): NS = bicarb; NAC = placebo for CIN prevention

POSEIDON trial: LVEDP-guided hydration superior in CHF patients undergoing PCI

AMACING trial: No prophylactic hydration was non-inferior in low-risk eGFR 45–59 — supports targeting hydration to high-risk patients

ACR-NKF 2020: Reframed CIN as CA-AKI; IV contrast safe in eGFR ≥30

Daily creatinine timing: 48–72 h post-contrast is the universal recheck

Discharge orders: Document creatinine, held meds, restart instructions, 5–7 day PCP follow-up

Board Question Stem Patterns

— 68-year-old diabetic, eGFR 38, needs coronary angiography. Best prevention strategy?

— Answer: IV isotonic saline 1 mL/kg/h for 6–12 h before and after, use low/iso-osmolar contrast, minimize volume, hold metformin and NSAIDs.

— Distractors: NAC (no longer recommended), prophylactic HD (harmful), mannitol (harmful)

— 72-year-old, day 2 post-PCI, creatinine 1.0 → 1.6, asymptomatic, urine output adequate. Next step?

— Answer: Supportive care, IV fluids if hypovolemic, hold nephrotoxins, recheck creatinine, expect peak day 3–5 and recovery by day 7–14.

— 6 weeks post-aortic cath, livedo reticularis, blue toes, eosinophilia, creatinine progressively rising, low C3. Diagnosis?

— Answer: Cholesterol atheroembolic disease (not CIN).

— Pregnant woman with suspected PE and elevated d-dimer. CT or V/Q?

— Answer: Either acceptable; if normal CXR and no chronic lung disease, V/Q preferred to reduce fetal/maternal radiation; iodinated contrast safe but minimize.

— Patient on metformin develops AKI after contrast, presents with abdominal pain, Kussmaul breathing, lactate 8. Diagnosis and management?

— Answer: Metformin-associated lactic acidosis; stop metformin, supportive care, possible hemodialysis.

— Best fluid for CIN prophylaxis?

— Answer: Isotonic saline or isotonic sodium bicarbonate (equivalent per PRESERVE).

— Need MRI in eGFR 22. Risk?

— Answer: Nephrogenic systemic fibrosis with older linear agents; Group II macrocyclic agents (gadobutrol, gadoteridol) have minimal risk and can be used when indicated.

— Dialysis-dependent ESRD needs CT with contrast. Schedule urgent HD after?

— Answer: No; contrast does not need urgent removal in dialysis patients without residual function.

Step 3 management: Recognize the trap answers — NAC, prophylactic HD, mannitol, and furosemide are nearly always wrong for CIN prevention.

Stem 1 — Prevention in diabetic CKD:

Stem 2 — Post-PCI rising creatinine:

Stem 3 — Atheroembolic mimic:

Stem 4 — Pregnancy:

Stem 5 — Metformin in AKI:

Stem 6 — Hydration choice:

Stem 7 — Gadolinium in CKD:

Stem 8 — Hemodialysis prophylactically:

One-Line Recap

Contrast-induced nephropathy is largely preventable by risk-stratifying patients with eGFR <30 (or <45 with diabetes/CHF), giving periprocedural IV isotonic crystalloid, minimizing contrast volume with low- or iso-osmolar agents, holding metformin/NSAIDs/SGLT2 inhibitors, and rechecking creatinine at 48–72 hours — with NAC, mannitol, furosemide, and prophylactic dialysis no longer playing a role.

Board pearl: When the answer choice list includes "IV isotonic saline" alongside NAC, mannitol, furosemide, and prophylactic HD — pick the saline. It is the only intervention with consistent guideline support across ACR, KDIGO, and NKF.

Recap 1 — Diagnosis: CIN is a clinical diagnosis of exclusion: creatinine rises within 24–48 h, peaks day 3–5, resolves by day 7–14, with FeNa paradoxically <1%; rule out obstruction, hypotension, atheroemboli (livedo, blue toes, eosinophilia at 3–8 weeks), AIN (WBC casts at 7–10 days), and HRS in cirrhotics.

Recap 2 — Prevention: IV isotonic saline or isotonic bicarbonate (equivalent per PRESERVE) 1–1.5 mL/kg/h for 6–12 h before and after contrast in patients with eGFR <30 or <45 with diabetes/CHF; choose low- or iso-osmolar agent; keep contrast volume (mL) < 3 × eGFR; hold NSAIDs, metformin (if eGFR <30 or AKI), SGLT2 inhibitors for 3 days, and ACEi/ARB if volume-depleted.

Recap 3 — What does NOT work: NAC (PRESERVE negative), mannitol, prophylactic furosemide, and prophylactic hemodialysis are all wrong answers on Step 3.

Recap 4 — Follow-up and safety: Every at-risk patient needs a 48–72 h post-contrast creatinine, documented medication restart plan, PCP follow-up within 5–7 days, and nephrology referral if eGFR remains <60 at 3 months; CIN is associated with increased long-term cardiovascular mortality, so intensify secondary prevention (BP <130/80, statin, glycemic control, smoking cessation).